May 21, 2026 | 09:00AM PST

WEBINAR OVERVIEW

The economics of drug development are changing — and the most sophisticated players in biotech, pharma, and investment are paying close attention. This DIA webinar brings together the architects of a groundbreaking new financing model that is already live in the market, exploring how validated Predictive AI is fundamentally transforming how clinical trial risk is assessed, financed, and insured. For the first time, a non-dilutive, insurance-backed capital pathway — powered by GATC Health's proprietary Derisq™ AI Report and endorsed by Lloyd's of London through MCI Syndicate 1966 — is available to biotech companies seeking to advance their most promising clinical programs with less risk and less dilution. Panelists will examine the convergence of validated Predictive AI, institutional insurance underwriting, and a first-of-its-kind clinical trial financing structure — the Phase+ program — through the perspectives of the technology, the deal structure, the investment banking community, and real-world biotech operators.

This session is designed for investment banks, buy-side analysts, biotech CEOs, and investors who are navigating capital formation challenges and seeking a deeper understanding of how AI-validated assets are reshaping deal flow, due diligence, and fundraising dynamics in clinical-stage development. Attendees will leave with a clear understanding of what the Derisq™ AI Report delivers, why Lloyd's of London's endorsement matters, and how the Phase+ program creates a new lever for capital formation — all backed by independently validated AI with 86% sensitivity and 91% specificity, assessed under blinded conditions.

FEATURED TOPICS:

At the conclusion of this activity, participants should be able to:

• Explain how GATC Health's Derisq™ AI Report uses multiomics-based biological simulation to predict drug candidate safety, efficacy, and off-target risk — and how its independently validated performance metrics (86% sensitivity, 91% specificity) translate to real-world clinical decision-making.
• Describe the structure of the Phase+ program and how it combines GATC Health's AI diligence with Lloyd's-backed insurance through MCI to create a first-of-its-kind non-dilutive financing option for Phase 1, 2, and 3 clinical trials.
• Articulate why Lloyd's of London's acceptance of GATC Health's AI platform as the basis for underwriting clinical trial risk represents a landmark validation signal for institutional investors and biotech stakeholders.
• Discuss how sophisticated buy-side capital and institutional investors are beginning to incorporate AI-validated data into due diligence frameworks, and what this means for deal flow dynamics and asset valuation.
• Evaluate how biotechs — including single-asset companies and those with multi-asset pipelines — can leverage the Phase+ program to reduce dilution, hedge development risk, and bring stronger evidence to partnership and fundraising conversations.
• Identify how AI-validated assets are beginning to differentiate in BD&L and capital markets conversations, and why early adoption of Predictive AI validation may represent a structural competitive advantage.